Toxicity of glufosfamide in Beagle dogs following intravenous injection

Journal of China Pharmaceutical University

Volumn 40, Issue 6, 2009, Pages 535-538

  Ding, Yan Wei ^a   Li, Zuo Kui ^a   Zhao, Hua ^a   Zhang, Jian Xin ^a   Li, Bao Qiu ^a,b  

^a Shandong Hongli Laboratory   (Thailand)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Beagle dog; Glufosfamide; Toxicity

Indexed keywords

ALKYLATING AGENT; GLUFOSFAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG MEGADOSE; DRUG SAFETY; LETHAL DOSE; LOW DRUG DOSE; NONHUMAN; ORGAN INJURY;

EID: 75649130833     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Ammons WS, Wang JW, Yang Z, et. al. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo [J]. Neoplasia,2007,9(8): 625-633.
2. Briasoulis E, Judson I, Pavlidis N, et al. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European organization for research and treatment of cancer early clinical studies group[J]. J Clin Oncol,2006,18(20): 3 535-3 544.
3. (Cao J). Glufosfamide FDA [J]. (World Pharm News) ,2005(3): 21.
4. Engel J, Klenner T, Niemeyer U, et al. Glufosfamide [J]. Drugs Fut,2000,25(8): 791.
5. Giacconea G, Smit EF, de Jonge M, et al. Glufosfamide administered by 1 -hour infusion as a second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC-New Drug Development Group[J]. Eur J Cancer, 2004,40(5): 667 -672.
6. Ciuleanu TE, Pavlovsky AV, Bodoky G, et al. A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine[J]. Eur J Cancer, 2009,45(9): 1 589-1 596.